NRG Oncology/RTOG 1119: PHASE II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery with Concurrent Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer — A Collaborative Study of NRG and KROG (NCT01622868)

The addition of trastuzumab/pertuzumab to chemotherapy improving outcomes overall for patients (pts) with HER2+ breast cancer. Increased survival coupled with limited blood-brain barrier (BBB) penetration of these agents may contribute to an increased incidence of brain metastases (BM) and half of these pts die of intracranial disease progression rather than extracranial disease. Therefore, strategies to improve survival must include increased...